Shares of Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $17.10, but opened at $18.34. Terumo shares last traded at $17.74, with a volume of 287,530 shares changing hands.
Terumo Stock Performance
The stock has a market capitalization of $25.64 billion, a P/E ratio of 33.31 and a beta of 0.79. The company has a quick ratio of 1.78, a current ratio of 3.00 and a debt-to-equity ratio of 0.12. The company has a 50-day moving average price of $17.76 and a two-hundred day moving average price of $18.35.
Terumo (OTCMKTS:TRUMY - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.07). The firm had revenue of $1.79 billion for the quarter, compared to analysts' expectations of $1.79 billion. Terumo had a net margin of 11.28% and a return on equity of 8.48%.
About Terumo
(
Get Free Report)
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.
Featured Articles
Before you consider Terumo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terumo wasn't on the list.
While Terumo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access